<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044561</url>
  </required_header>
  <id_info>
    <org_study_id>amr el-sayed 2017</org_study_id>
    <nct_id>NCT03044561</nct_id>
  </id_info>
  <brief_title>Sildenafil Citrate of in Vitro Fertilization After Multiple IVF Failures Attributed to Poor Endometrial Development</brief_title>
  <official_title>Effect of Sildenafil Citrate on the Outcome of in Vitro Fertilization After Multiple IVF Failures Attributed to Poor Endometrial Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of sildenafil citrate on endometrial
      development in women with history of recurrent implantation failure after IVF
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      sildenafil citrate may increase endometrial thickness in women with recurrent IVF failure
      attributed to poor endometrial development
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2017</start_date>
  <completion_date type="Anticipated">August 10, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endometrial thickness measures</measure>
    <time_frame>21 days</time_frame>
    <description>we will measure endometrial thickness by US in women with recurrent implantation failure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>IVF Failure</condition>
  <arm_group>
    <arm_group_label>Sildenafil citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate</intervention_name>
    <description>25 mg orally, 4 times per day for 21 days</description>
    <arm_group_label>Sildenafil citrate</arm_group_label>
    <other_name>Silden 25 mg tablet, EIPICO, Inc, Cairo, Egypt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>orally, 4 times per day for 21 days</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) cases of infertility, older than 20 years of age and not older than 40 years.

          -  (2) Body mass index (BMI):20-29.

          -  (3) women have experienced two or more implantation failure attributed to inadequate
             endometrial development.

        Exclusion Criteria:

          -  (1) Uterine abnormalities (e.g. septate, bicornuate and fibroid uterus, Asherman
             Syndrome).

          -  (2) Any contraindication to sildenafil citrate or any of the components of its
             formulation including:

               -  Concurrent use of organic nitrites and nitrates.

               -  Severe hepatic impairment.

               -  Severe renal impairment.

               -  Hypotension.

               -  Recent stroke or heart attack.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ahmed khairy, professor</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ahmed khairy, professor</last_name>
    <phone>01090808047</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Ain shams university</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>amr elsayed</last_name>
      <phone>01090808047</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Amr El-Sayed</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>August 9, 2017</submitted>
    <returned>September 6, 2017</returned>
    <submitted>February 5, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

